Notably, the co-occurrence of KRAS and KEAP1 mutations has been linked to poorer clinical outcomes and reduced therapeutic efficacy in non-small cell lung cancer, further supporting a potential cooperative role of KEAP1 alterations and MAPK activation (73). The gene discussed is KEAP1; the disease is non-small cell lung carcinoma.